MedTrace Logo

Development of an Information Board and Mobile Application for the Care of Type 2 Diabetes

NCT04974333 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1512

Last updated 2022-03-31

No results posted yet for this study

Summary

The SANENT trial is a primary care-based, prospective, two-arm, randomized controlled, open-label, blinded-endpoint study with the aim to compare a diabetes management strategy using an information board and a mobile application versus standard care in patients with uncontrolled type 2 diabetes. This trial aims to recruit 1440 type 2 diabetes patients during a period of six months until the requested number of participants have been achieved. The total length of the intervention will be one year. The SANENT trial protocol is presented according to Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) recommendations

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DEVICE

Mobile health application on phone

Patients will use a mobile app on their smart phones

Sponsors & Collaborators

  • Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

    collaborator OTHER_GOV

  • Eli Lilly and Company

    collaborator INDUSTRY

  • General Health Council, Mexico

    lead OTHER_GOV

Principal Investigators

  • Nelly Cisneros Gonzalez, MD · Consejo General de Salud

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-04
Primary Completion
2023-08-31
Completion
2024-02-28

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04974333 on ClinicalTrials.gov